September 4, 2023 – Goldea Capital

Brady Corporation increases its dividend to shareholders for the 38th consecutive year

Written by Customer Service on September 4, 2023. Posted in Dividend Reports And Estimates.

MILWAUKEE, Sept. 04, 2023 (GLOBE NEWSWIRE) — On August 30, 2023, Brady Corporation’s (NYSE: BRC) Board of Directors approved an increase in the annual dividend to shareholders of the Company’s Class A Common Stock from $0.92 per share to $0.94 per share. A quarterly dividend to shareholders of the Company’s Class A Common Stock of $0.235 per share will be paid on October 31, 2023, to shareholders of record at the close of business on October 10, 2023. This dividend represents the 38th consecutive annual increase in dividends. Brady Corporation is an international manufacturer and marketer of complete solutions that identify and protect people, products and places. Brady’s products help customers increase safety, security, productivity and performance and include high-performance labels, signs, safety devices, printing systems...

Silk Road Medical to Present at the CL King 21st Annual Best Ideas Conference

Written by Customer Service on September 4, 2023. Posted in Public Companies.

SUNNYVALE, Calif., Sept. 04, 2023 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that management will present at the CL King 21st Annual Best Ideas Conference. Management is scheduled to present on Monday, September 18, 2023, at 8:45 a.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: https://investors.silkroadmed.com/. About Silk Road MedicalSilk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, and Plymouth, Minnesota, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called...

Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights

Written by Customer Service on September 4, 2023. Posted in Earnings Releases And Operating Results.

Georges Rawadi was appointed Chief Executive Officer as from April 27, 2023 Celyad Oncology has received approximately EUR 9.8m in private placement commitments from historical shareholders Encouraging progress in multiplex shRNA platform development, which allows now targeting of up to four genes simultaneously, were presented at international meetings In vitro validation of NKG2D-based multi-specific CAR T-cell platform with a first candidate targeting both NKG2D ligands and CD19 was also presented MONT-SAINT-GUIBERT, Belgium, Sept. 04, 2023 (GLOBE NEWSWIRE) — Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces its financial results and recent business developments for the first half year, ended June 30, 2023. “Celyad Oncology is now fully focused on maximizing the potential of its proprietary...

Solvay SA: liability management update

Written by Customer Service on September 4, 2023. Posted in Public Companies.

THIS ANNOUNCEMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT QUALIFIED OR MAY HAVE QUALIFIED AS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE MARKET ABUSE REGULATION (EU) 596/2014 (“MAR”). Solvay SA: liability management update Consents on 2025 and 2027 Bonds Successful Tender on 2024 Hybrid Bonds Successful 2029 Bonds to be Redeemed, Trade under Review, No Bondholder Meeting Brussels, 4 September 2023 at 9.00pm CEST – As part of the consent solicitation announced on 4 August 2023 in relation to Solvay SA (“Solvay” or the “Company”)’s €600,000,000 0.500 per cent. Fixed Rate Bonds due 6 September 2029 (ISIN: BE6315847804) (the “2029 Bonds”), Solvay has become aware that votes cast in favor of the consent representing less than 3% of the total nominal amount may not have been validly exercised. At this stage,...

Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Written by Customer Service on September 4, 2023. Posted in Public Companies.

Company Announcement Phase 3 innovaTV 301 confirmatory trial met its primary endpoint of improved overall survival (OS) at predetermined, independent interim analysis Trial results to be submitted for presentation at a future medical meeting Genmab and Seagen to engage in discussions with regulatory authorities COPENHAGEN, Denmark, and BOTHELL, Wash.; September 4, 2023 – Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) announced today that the Phase 3 innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy who received TIVDAK® (tisotumab vedotin-tftv), compared with chemotherapy alone, met its primary endpoint of overall survival (OS). An Independent Data Monitoring Committee determined that OS crossed the pre-specified efficacy boundary at interim...

Nokia Corporation: Repurchase of own shares on 04.09.2023

Written by Customer Service on September 4, 2023. Posted in Public Companies.

Nokia CorporationStock Exchange Release4 September 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 04.09.2023 Espoo, Finland – On 4 September 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code) Number of shares Weighted average price / share, EUR* XHEL 250,191 3.75 CEUX 79,299 3.75 AQEU 27,302 3.75 TQEX 19,208 3.76 Total 376,000 3.75 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation...

Press release : Orange successfully completes its inaugural sustainability-linked bond issuance for EUR 500M

Written by Customer Service on September 4, 2023. Posted in Public Companies.

Press release Paris, 04 September 2023 Orange successfully completes its inaugural sustainability-linked bond issuance for EUR 500M Orange has successfully issued its first sustainability-linked bond, for a nominal amount of EUR 500 million, linked to the company’s target to reduce by -45% its absolute greenhouse gas emissions (Scope 1, 2 & 3) by 2030 (vs. 2020) and its commitment to provide digital support and training to external beneficiaries (6 million beneficiaries cumulatively between 2021 and 2030). This GHG reduction target is aligned with the objective to keep global warming at 1.5°C and has been submitted to SBTi for validation. Currency Format Term Notional Coupon Re-offer spread EUR Fixed rate 2035 500 million 3.875% m/s + 72bps This issuance follows Orange’s recently published Sustainability-Linked...

Global Corrosion Inhibitors Market Size to Reach USD 17.67 Billion in 2032 | Emergen Research

Written by Customer Service on September 4, 2023. Posted in Mergers And Acquisitions.

Increasing development of bio-based and more ecofriendly products is a major factor driving market revenue growth Vancouver, Sept. 04, 2023 (GLOBE NEWSWIRE) — The projected value of the global corrosion inhibitors market is anticipated to attain USD 17.67 billion by 2032, displaying a consistent compound annual growth rate (CAGR) of 5.0% throughout the forecast period, as indicated by the most recent analysis conducted by Emergen Research. A significant catalyst behind the advancement in market revenue is the rigorous directives pertaining to the utilization of corrosion inhibitors across various industries. These directives have been established with the primary goal of safeguarding both human well-being and the environment, while simultaneously ensuring the safety of products and systems that integrate corrosion inhibitors. A...

Government accounts 2022: improved performance and positive primary balance

Written by Customer Service on September 4, 2023. Posted in Public Companies.

The overall outcome of Part A-1 of the Government accounts for 2022 is nearly ISK 100m more favourable than was provided for in the 2022 National Budget, and about ISK 50bn better than estimated in late 2022. The overall outcome was negative by just under ISK 89bn, well below the estimated ISK 186bn deficit assumed in the National Budget. The primary balance is now positive by ISK 6.7bn, whereas it was projected to be negative by ISK 131bn according to the National Budget as approved by Parliament. The improvement therefore amounts to nearly ISK 138bn. The primary balance is the Treasury outcome before tax income and expenditures. The results of the Government accounts for 2022 have now been published, and the accounts have been sent to Parliament. The post-pandemic economic recovery in 2022 was strong in Iceland. GDP growth was strong,...

GN moves to “one company” governance structure; appoints Peter Karlstromer to Group CEO

Written by Customer Service on September 4, 2023. Posted in Public Companies.

The GN Group has a long and proud history as a technology innovator and, today, enjoys strong positions in attractive hearing, enterprise collaboration, and consumer gaming markets. In recent years, GN has increasingly expanded collaboration and integration across its two business divisions, GN Hearing and GN Audio, thus benefitting from joint innovation and leveraging combined scale to drive growth and profitability. GN’s Board of Directors has now decided to execute the next step of integration and transition into a one-company setup, simplifying the Group’s governance structure to drive further market success and shareholder value creation as a fully integrated innovation powerhouse. This includes a transition into one company with one Board, one Group CEO, and one Group CFO. The Board has appointed Peter Karlstromer as the Group...

Day: September 4, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice